三元生物(301206.SZ):美國啟動赤蘚糖醇雙反調查
格隆匯12月16日丨三元生物(301206.SZ)公佈,公司於近日獲悉,美國擬對原產於中國的赤蘚糖醇產品啟動反傾銷、反補貼調查(以下簡稱"雙反"調查)。
本次對中國赤蘚糖醇的"雙反"尚處於調查階段,對公司生產、經營的影響存在不確定性。公司已成立專案工作小組積極應對本次"雙反"調查,同時將密切關注並持續跟進調查的進展情況,堅決維護公司及全體股東的合法權益,並根據有關規定及時履行信息披露義務,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.